Black Bird Biotech, Inc.
BBBT
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -60.97% | -49.04% | -34.45% | -21.05% | 11.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.97% | -49.04% | -34.45% | -21.05% | 11.51% |
| Cost of Revenue | -7.82% | -42.44% | -32.46% | 4.83% | -53.98% |
| Gross Profit | -133.76% | -112.15% | -55.56% | -132.14% | 218.32% |
| SG&A Expenses | -82.89% | -76.09% | -50.26% | -12.33% | 69.14% |
| Depreciation & Amortization | -96.35% | -80.56% | -56.40% | -22.76% | 46.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -81.61% | -74.73% | -49.67% | -12.18% | 55.84% |
| Operating Income | 82.67% | 76.18% | 50.67% | 11.55% | -59.08% |
| Income Before Tax | 63.70% | 63.26% | 44.79% | 8.42% | -79.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.70% | 63.26% | 44.79% | 8.42% | -79.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.70% | 63.26% | 44.79% | 8.42% | -79.76% |
| EBIT | 82.67% | 76.18% | 50.67% | 11.55% | -59.08% |
| EBITDA | 98.47% | 88.19% | 60.03% | 10.95% | -133.73% |
| EPS Basic | 80.25% | 76.04% | 60.64% | 36.90% | 53.71% |
| Normalized Basic EPS | 77.55% | 74.14% | 57.14% | 32.00% | 55.05% |
| EPS Diluted | 80.25% | 76.04% | 60.64% | 36.90% | 53.71% |
| Normalized Diluted EPS | 80.00% | 75.93% | 58.49% | 37.50% | 57.94% |
| Average Basic Shares Outstanding | 152.63% | 66.65% | 55.70% | 65.06% | 104.99% |
| Average Diluted Shares Outstanding | 204.13% | 98.52% | 49.37% | 67.51% | 105.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |